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Objective: Calciphylaxis, a disorder of calcium-phosphate metabolism that can result in arterial calcification, skin and solid
organ calcium deposits, and nonhealing ulcerations, is associated with significant morbidity and mortality. Although its
most common cause is secondary hyperparathyroidism in patients with renal failure, vascular surgeons are frequently
called on to evaluate these nonhealing extremity wounds. We reviewed our experience of a multidisciplinary approach in
treating patients with calciphylaxis and nonhealing ulcers.
Patients and Methods: Over a 14-month period at a tertiary center, five patients were seen with calciphylaxis and
nonhealing leg wounds. Demographics, disease characteristics, surgical treatment, and outcomes were analyzed.
Results: All five patients were black women aged 40  8.9 years with hypertensive renal failure undergoing long-term
hemodialysis (80 43 months). They had large, painful lower extremity wounds or necrotic ulcers (mean size, 135 cm2)
that had developed over 2 to 4 months. Three patients had palpable pedal pulses, one patient had Doppler pedal signals,
and one patient had absent pedal flow. Arteriogram was performed in the latter two patients, and one patient underwent
lower extremity revascularization because of superficial femoral artery stenosis with symptomatic improvement. Four
patients underwent aggressive debridement by the vascular surgical service, and two needed plastic surgeon-performed
skin grafting. All patients had elevated parathyroid hormone levels (mean, 1735 pg/mL; > 25 normal level); mean
preoperative calcium levels were normal (10 mg/dL). After either subtotal (n 4) or total (n 1) parathyroidectomy by
an experienced endocrine surgeon, a significant reduction in parathyroid hormone and calcium levels was seen (122
pg/mL and 7.9 mg/dL, respectively; P < .05). There were no postoperative complications or amputations; one patient
died 12 months after parathyroidectomy of severe preexisting cardiopulmonary disease. Complete wound healing was
observed by 4.8 2 months. During a mean follow-up period of 9 months (range, 1 to 18 months), all wounds remained
healed without ulcer recurrence.
Conclusion: The diagnosis of calciphylaxis should be considered in patients with end-stage renal disease with atypical
tissue necrosis or subcutaneous nodules. Early recognition of calciphylaxis and multidisciplinary treatment, including
diligent wound care, frequent debridement, parathyroidectomy, and appropriate skin grafting or revascularization, can
result in improved wound healing and limb salvage. (J Vasc Surg 2003;37:501-7.)
Calciphylaxis is characterized by excessive calcium dep-
osition in skin, arteries, and other organs that develops as a
complication of secondary hyperparathyroidism, which
most commonly occurs in patients with end-stage renal
disease (ESRD). Up to 4% of patients for renal dialysis may
show signs of calciphylaxis,1 which range from painful
subcutaneous nodules to nonhealing extremity ulcers and
gangrene. Although the pathogenesis of such extensive
calcium deposition is unknown,2 the reported natural his-
tory is one of progression to poor wound healing, limb loss,
and even death in a large number of patients.3,4
The recognition of calciphylaxis relies on heightened
clinical awareness of the presence of atypical skin nodules or
ulcers that occur in patients with hemodialysis dependence.
On encountering a patient with ESRD with such skin
lesions, additional biochemical evaluations are critical to
confirm the state of hyperparathyroidism and thus establish
the diagnosis of calciphylaxis. Although serum levels of
calcium, phosphate, alkaline phosphatase, and parathyroid
hormone (PTH) are important diagnostic considerations,
no one abnormality is pathognomonic for calciphylaxis.5
Vascular surgeons are usually the first physicians called on
to evaluate such patients on the basis of a nonhealing
extremity wound and a presumption of underlying periph-
eral arterial occlusive disease.3,4 The prevalence of periph-
eral vascular disease requiring surgical intervention among
patients with calciphylaxis is difficult to determine from
limited case reports.3,4,6 Early management of calciphylaxis
has traditionally consisted of local wound care, aggressive
dialysis regimens, and calcium-lowering and phosphate-
lowering medications. The importance of surgical interven-
From the Department of General Surgery, Cleveland Clinic Foundationa;
The Cardiac and Vascular Centerb;
the Department of Vascular Surgery, Baylor College of Medicinec;
Certified Wound, Ostomy, and Continence, Visiting Nurse Serviced;
Plastic Surgery, Piedmont Hospitale;
the Department of Surgery, Emory University School of Medicine.f
Competition of interest: none.
Reprint requests: Thomas F. Dodson, MD, Division of Vascular Surgery,
Emory University Hospital Department of Surgery, 1364 Clifton Rd, NE,
Atlanta, GA 30322 (e-mail: thomas_dodson@emoryhealthcare.org).
Published online Jan 15, 2003.
Copyright © 2003 by The Society for Vascular Surgery and The American




tions, such as arterial revascularization and especially para-
thyroidectomy, has likewise been emphasized although not
routinely recommended to all patients.6,7
We reviewed our recent experience with this rare con-
dition in the context of multidisciplinary treatment pro-
vided to these patients at our institution. Our aim was to
characterize features of calciphylaxis or components of
treatment that may lead to improved outcome.
PATIENTS AND METHODS
During a 14-month interval from June 2000 to August
2001, five patients were seen consecutively at the vascular
surgery center at a tertiary referral hospital (Emory Univer-
sity Hospital) with calciphylaxis and nonhealing leg
wounds. Patients characteristics (age, gender, race, diagno-
sis of underlying kidney disease, duration of hemodialysis)
and clinical variables (serum calcium, phosphate, intact
PTH, alkaline phosphatase) were obtained initially and at
subsequent examinations. The mean calcium phosphate
product (calcium  phosphate; mg2/dL2) was calculated
for each patient. The duration and extent of symptoms of
calciphylaxis, responses to medical management of hyper-
parathyroidism, prior kidney transplantation, and prior par-
athyroidectomy were noted. History of peripheral vascular
disease and interventions and clinical vascular examination
results were recorded for each patient. Operative and post-
operative data were accumulated from chart review for
revascularization procedures, wound debridement, and
parathyroidectomy.
Wound care was performed by the Wound, Ostomy,
and Continence (WOC) nurses on a weekly basis both
before and after surgery, and extremity ulcers were mea-
sured and photographed until fully healed. Local wound
care consisted of daily application of a hydrogel (Curasol,
Healthpoint, Fort Worth, Tex) with normal saline moist
gauze dressing for clean wounds or for wounds with tissue
slough. Transparent adhesive dressings (OpSite, Smith &
Nephew, Largo, Fla) were used for wounds with eschar to
encourage autolytic debridement. Exudative wounds were
covered with calcium alginates (Kaltostat, Convatec,
Princeton, NJ) and a hydrocolloid wafer dressing (Duo-
derm CGF, Convatec).
The patients and their families continued daily wound
care by themselves at home between clinic visits. WOC
nurses performed detailed wound care teaching in clinic
until the patients were comfortable with the procedure.
None of the patients needed a visiting home nurse. Family
members assisted with dressing changes to large wounds on
the posterior of legs or areas difficult to reach.
Amputation, postoperative wound infections or medi-
cal complication, and mortality rates were determined dur-
ing the follow-up interval. The late status of patients was
established with office visit and follow-up patient interview.
Statistical analysis of the data was performed with the use of
Student t test for paired variables, denoting a P value of less
than .05 as statistically significant.
RESULTS
All five patients were black women who were hemodi-
alysis dependent with a mean age of 40  8.9 years. The
cause of the renal failure was hypertension; two of the five
patients also had insulin-dependent diabetes mellitus. The
mean duration of hemodialysis was nearly 7 years (80 43
months). Three of the five patients had received kidney
transplantation 3 to 5 years before the current presentation
and had resumed hemodialysis after kidney graft failure for
at least 1 year before development of extremity wounds. All
except one patient were aware of the underlying diagnosis
of hyperparathyroidism. Other comorbid conditions iden-
tified in this group of patients included cardiac disease
(2/5), asthma (3/5), peripheral vascular disease (1/5),
gastrointestinal problems (3/5), and chronic cigarette
smoking (2/5).
All patients fit the criteria for a clinical diagnosis of
calciphylaxis. Lower extremity wounds were present in all
five patients. The mean initial size of the wounds was 135
165 cm2, typically consisting of a contiguous skin defect of
approximately 10  10 cm (Fig 1). The largest wounds
affected a 52-year-old woman with three separate patches
of ulceration (14  9 cm, 18  3.5 cm, 13.5  5 cm)
distributed circumferentially around the left lower leg. No-
table wound characteristics among the patients included
ulceration with thick eschar (4/5), blistering (1/5), severe
local tissue pain and bony aches (3/5), pruritus (2/5),
painful subcutaneous nodules (1/5), and location limited
to proximal thigh and buttocks (2/5) or distal lower leg
(3/5). None of the patients showed signs of local wound
infection, such as cellulitis, or signs of systemic sepsis. Three
of the five patients reported similar but smaller wound
problems in the past that had resolved spontaneously. The
current wounds developed over a period of 2 to 4 months.
Tissue biopsy of one wound was obtained by a referring
physician but did not reveal vascular calcifications; none of
Fig 1. Characteristic appearance of calciphylaxis wound with su-
perficial ulceration and thick black eschar covering underlying
necrotic tissue.
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the other four patients had tissue biopsy for diagnostic
purposes. The patients were symptomatic for an average of
3 0.8 months before referral for initial surgical evaluation
to a vascular surgeon.
Hyperparathyroidism was confirmed in all five patients
with elevation of PTH levels, which ranged from 538 to
3515 pg/mL (mean, 1735 1190 pg/mL; normal range,
10 to 65 pg/mL). Mean preoperative calcium measure-
ments were normal (10  0.9 mg/dL), but phosphorus
(4.9 0.6 mg/dL) and alkaline phosphatase (778 1193
mg/dL) levels were high. All patients had been treated
chronically with intensified dialysis regimens and phos-
phate-lowering medications (sevelamar [Renagel, Gen-
zyme Corp, Cambridge, Mass], calcium acetate [Phoslo,
Braintree Laboratories, Braintree, Mass]). The calcium-
phosphate product, thought to be suggestive of calciphy-
laxis if greater than 70 mg2/dL2,1,5 was 50 10 mg2/dL2
before surgery. One of the five patients had a prior subtotal
(31⁄2 gland) parathyroidectomy; the presenting PTH value
was 1000 pg/mL, indicating recurrent renal hyperparathy-
roidism. Two patients had significant osteoporosis as deter-
mined with abnormal bone density.
Clinical vascular history was unremarkable, and palpa-
ble pedal pulses were detected in three of the five patients.
Ankle-brachial index measurements were not obtainable
because of severe pain from application of the pressure cuff
and large wounds in the area. One patient had Doppler
pedal signals but no prior known vascular problems, and
one patient had absent pedal flow. Arteriogram was per-
formed in these two patients, and results were abnormal in
only the last patient. This was a 52-year-old woman with
painful necrotic ulcers circumferentially around the left
lower leg and extensive history of peripheral vascular dis-
ease, including right common femoral endarterectomy and
later right femoral-popliteal bypass. The patient underwent
left lower extremity revascularization for superficial femoral
artery stenosis (Fig 2) with reversed saphenous vein graft
femoral-popliteal bypass as the initial treatment on diagno-
sis with calciphylaxis. At 18-month follow-up, this patient
remained ambulatory with completely healed wounds and
palpable dorsalis pedis pulses in both feet.
Treatment of these five patients required the coordi-
nated efforts of a team of surgeons (vascular, endocrine,
plastic), nephrologists, and WOC nurses. Four patients
underwent aggressive debridement of wounds in the oper-
ating room by the vascular surgical service. Two patients
needed plastic surgeon-performed skin grafts. All five pa-
tients received subtotal (n  4) or total (n  1) parathy-
roidectomy by an experienced endocrine surgeon. Evalua-
tion by endocrine surgery was obtained within a week of
initial presentation to a vascular surgeon, and parathyroid-
ectomy and wound debridement were accomplished dur-
ing the same hospital stay. WOC nurses performed daily
wound care during inpatient hospitalization and monitored
healing weekly during clinic follow-up visits.
There were no postoperative complications or amputa-
tions. One patient died 12 months after parathyroidectomy
from severe preexisting cardiopulmonary disease. After par-
athyroidectomy, there was a significant reduction (P .05)
in levels of PTH (122  48 pg/mL), calcium (7.9  1.6
mg/dL), calcium-phosphate product (36  8 mg2/dL2),
and alkaline phosphatase (560 819 mg/dL). The radical
extent of parathyroidectomy should be noted (Fig 3) be-
cause this is crucial to interrupting the abnormal patho-
physiology driving hyperparathyroidism and calciphylaxis
and decreases chances of persistent and recurrent hyper-
parathyroidism in the future.1,7 Total parathyroidectomy
without implantation of parathyroid tissue was performed
in one patient with recurrent secondary hyperparathyroid-
ism. All four parathyroid glands were enlarged in the re-
maining patients, and total parathyroid volume per patient
averaged 1883  858 mm3. A remnant measuring only
74.2 47 mm3 was left in the neck as the sole parathyroid
tissue. This is roughly equivalent to two normal parathy-
roids. Intraoperative PTH measurement, with final goal of
PTH 100 to 200 pg/mL, and parathyroid tissue cryo-
preservation allow such radical removal of tissue without
rendering the patient hypocalcemic.
Fig 2. Arteriogram shows diffuse aortoiliac disease and left superficial femoral artery occlusion in patient with
calciphylaxis ulcers of left lower leg. Patient underwent left femoral-popliteal bypass with reversed saphenous vein graft,
followed by wound debridement and parathyroidectomy.
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The most vital outcome was that complete healing of
these large wounds was observed by 4.8  2 months (Fig
4). The rate of wound healing was proportional to the size
of the tissue defect. Two patients whose extremity wounds
measured 18.3 and 35 cm2 achieved full reepithelialization
in 3 months, whereas larger wounds, 257 and 364 cm2 in
size and circumferential, needed skin grafting and ulti-
mately fully healed by 7 months. Resolution of pain and
bony aches occurred faster, with improvement noted by
patients even during initial hospitalization. This was mani-
fested in an obvious manner, for example, by the improved
ability of patients to tolerate touching of the extremity and
dressing changes. During a mean follow-up period of 9
months (range, 1 to 18 months), all wounds remained
healed without ulcer recurrence.
DISCUSSION
Calciphylaxis is a relatively rare and disabling condition
that presents both diagnostic and treatment challenges. A
precise etiology of calciphylaxis remains undefined, al-
though as early as 1962, Selye8 recognized this as a system-
atic condition of rapid calcium deposition and was able to
use sensitizing agents (PTH) and challenging agents (egg
whites) to produce calcification in the skin of experimental
rats. Histologic examination in human tissues most often
reveals small vessel involvement with medial calcification,
intimal proliferation, microthrombi, and extravascular cal-
cium deposits.9,10 The clinical syndrome in patients associ-
ates ESRD, secondary hyperparathyroidism, and painful
cutaneous lesions; these are the components critical to
entertaining a diagnosis of calciphylaxis. Failure to under-
stand better the pathophysiology linking these three con-
ditions contributes to the delay in diagnosis and adminis-
tration of currently available treatments.
Our data present a group of patients with the represen-
tative combination of clinical features of calciphylaxis. Di-
agnosis is usually achieved because of heightened clinical
suspicion, rather than the presence of any pathognomonic
findings. The most important of serum blood tests are
measurements of PTH, calcium, and phosphate because
these establish the diagnosis of secondary hyperparathy-
roidism and can be followed as markers of adequate medical
management and dialysis for parathyroid hyperplasia. Al-
though the female preponderance in our series is also
typical of previously reported calciphylaxis cases, factors
contributing to such an epidemiologic predilection remain
less clear.7,11
Neither skin biopsies nor radiologic studies are specific
for calciphylaxis,2 although they may be supportive of the
diagnosis.4,10 Only one of our patients had skin biopsy
performed before referral, and this revealed dermal and
epidermal changes of stasis dermatitis without vascular
calcifications. With calciphylaxis, one might expect to find
calcium deposits in subcutaneous tissue and arterial calcifi-
cations obliterating small blood vessels; calcium concen-
trated in the media of vessel walls has been described.10,12
Similarly, roentgenograms of legs and feet may disclose an
outline of arterial calcifications.9,12 None of these manifes-
tations are observed consistently enough to be reliable
diagnostic tools.
There is no diagnostic threshold level for PTH, cal-
cium, or phosphate elevations,6 although these remain
Fig 3. Hyperplasia of all parathyroid glands is prominent in secondary hyperparathyroidism seen in patients with
calciphylaxis. Radical resection leaving small parathyroid remnant is guided with intraoperative PTH measurement.
Less complete resection risks persistent and recurrent hyperparathyroidism and failure to improve extremity wounds.
Parathyroid designations: LL, left lower; LU, left upper; RL, right lower; RU, right upper; SR, subtotal resection.
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essential components of any evaluation of calciphylaxis.
Preoperative PTH levels in this group of patients with
calciphylaxis were, in fact, comparable with those reported
in literature for renal hyperparathyroidism in general,
which range from 619 to 4160 pg/mL.13,14 There is no
evidence that the degree of PTH elevation alone is related
to severity of parathyroid disease or other consequences of
hyperparathyroidism, such as calciphylaxis ulcers. Some
surgeons advocate consideration of parathyroidectomy for
all patients with dialysis-dependent renal disease when
PTH levels exceed 500 pg/mL.15,16 The experience na-
tionally is that only about 2.5% of patients with ESRD will
eventually undergo parathyroidectomy.13 This is lower
even than the estimated prevalence rate (4%) of calciphy-
laxis in the ESRD population.1 Such statistics are a re-
minder that most patients with ESRD receive medical
management for control of parathyroid hypersecretion.
Aggressive dialysis, prevention of phosphate retention and
hyperphosphatemia, maintenance of normal calcium levels,
and use of calcitriol (1, 25-dihydroxyvitamin D) have been
traditional components of medical therapy.13,17 All of our
patients had optimal medical management that, neverthe-
less, was insufficient to control the hyperparathyroidism. A
recent review highlights the observation that although
medical treatment is an important first intervention, this
has not altered the course of hyperparathyroidism despite
better medical regimens over the last 10 years; a constant
number of patients will need parathyroidectomy and, like
ours, be referred for this procedure late in the disease
process.13
Elevated calcium-phosphate product greater than 70
mg2/dL2 has been suggested as supportive of calciphylax-
is.1,5 Although the mean value of this product in our group
of patients initially was only 50 mg2/dL2, it did decrease
significantly (36 mg2/dL2; P  .05) after parathyroidec-
tomy. It is important to recognize that the calcium-phos-
phate product has not been advocated as a definitive diag-
nostic finding of calciphylaxis, even in literature reporting
higher values in patients with calciphylaxis.1 Elevated calci-
um-phosphate product has been suggested as partially re-
sponsible for the disease process of soft tissue calcifications,
although the pathophysiologic mechanism has still not
been elucidated.18 Series of patients with calciphylaxis have
reported both high1,9 and normal to slightly elevated cal-
cium-phosphate products.3,7,16 Until this disease process is
better understood, the role of the calcium-phosphate prod-
uct can best be described as supportive of calciphylaxis, if
elevated, but not excluding calciphylaxis if lower than an-
ticipated.
The role of the vascular surgeon is pivotal in our
multidisciplinary experience with this disease. Our institu-
tional experience has been that vascular surgeons are typi-
cally the first to consider and confirm the diagnosis of
calciphylaxis because these patients are initially referred to
Fig 4. Complete ulcer healing was observed in all patients by 4.8  2 months. Two patients, including one shown,
needed skin grafting for tissue coverage.
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them out of concern for peripheral vascular disease. Be-
cause of the high incidence rate of atherosclerotic vascular
disease in patients with ESRD, the distinction between
calciphylaxis wounds and ischemic ulcers is important. It is
essential to exclude underlying vascular disease with clinical
examination and angiography if appropriate. Ulcers located
more proximally on the extremity, preserved peripheral
pulses, absence of neuropathy, associated subcutaneous
nodules, and symptoms of extreme pain are more likely
with calciphylaxis wounds. It is difficult to assess accurately
the prevalence of true peripheral vascular disease in patients
with calciphylaxis. The prevalence rate of peripheral vascu-
lar disease is known to be as high as 34% among patients
with ESRD.20 Among 55 cases of calciphylaxis, including
ours, that were recently described,1,3,4,6,7,12,21-23 arteriog-
raphy was reported for only six patients,4,23 three of whom
went on to have lower extremity revascularization4 with a
67% postoperative complication rate. On the basis of this
small group of patients, firm recommendations regarding
revascularization in patients with calciphylaxis would be
unfounded. It seems reasonable to suggest that surgical
correction of underlying obstructive arterial disease may
have an appropriate role, but such treatment should be
individualized with respect to the overall medical condition
of the patient and the timing of other needed interventions,
such as parathyroidectomy.
Remarkably, in this series of five patients with extensive
calciphylaxis wounds, there were no amputations and no
postoperative cardiac complications. Complete wound
healing and pain relief was attained within a few months
after initial wound debridement and parathyroidectomy.
Only one patient died at 1 year of follow-up of reasons
unrelated to calciphylaxis. These results are encouraging
but atypical in comparison with morbidity and mortality
rates reportedly as high as or higher than 75% in other
calciphylaxis series.4,7 The explanation is undoubtedly mul-
Fig 5. Multidiscliplinary treatment algorithm for calciphylaxis. Surgical procedures can be coordinated during same
hospitalization. Vascular surgeon may also be important in assessing need for initial wound debridement and
subspecialty referrals.
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tifactorial and may involve all of the following elements:
prompt diagnosis of calciphylaxis, aggressive multidisci-
plinary care, early and radical parathyroidectomy with sig-
nificant reduction of PTH levels, diligent wound care,
younger or less chronically ill patients, and elimination of
inflammatory mediators that may be produced by the para-
thyroid glands.24 Like the mechanism of calciphylaxis itself,
the mechanism of this healing process needs to be better
understood. The observation remains, however, that even
as drastic and debilitating as the calciphylaxis wounds ap-
pear, they do seem to heal.
Early recognition of calciphylaxis and multidisciplinary
treatment, including wound debridement, parathyroidec-
tomy, and appropriate arterial revascularization, can lead to
improved wound healing and limb salvage. The number of
patients in our report is admittedly small, which undoubt-
edly limits recommendations on the basis of our clinical
experience. However, until more is understood about this
disorder, we recommend the multidisciplinary approach as
outlined in Fig 5. In our setting, the respective roles of the
vascular, endocrine, and plastic surgeons were determined
by preexisting referral patterns and surgical traditions in
caring for certain disease states. Just as it is important to
exclude a surgically correctable vascular lesion, it is even
more important to consider calciphylaxis in the differential
diagnosis. This allows thorough diagnostic evaluation of
the patient and recruitment of appropriate specialists,
whose roles may vary between institutions and include a
mixture of general surgeons or other specialists. The diag-
nosis of calciphylaxis should be considered early by all
physicians who encounter patients with ESRD and atypical
painful extremity wounds. The goals of treatment should
be improvement of wound healing and preservation of
functional limbs, reduction of pain, and correction of the
underlying hyperparathyroidism.
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